Lion’s Phase 2 study of lead product, LN-144, for the treatment of refractory, metastatic melanoma continues uninterrupted

Source: http://www.marketwired.com/mw/release.do?id=2115520&sourceType=3

This entry was posted on Sunday, April 17th, 2016 at 10:00 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.